Login / Signup

Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients.

Veronica Di CristanzianoPatrick AffeldtMoritz TrappeMaike WirtzEva HegerElena KnopsRolf KaiserDirk Ludger StippelRoman-Ulrich MüllerUdo HoltickChristoph ScheidMartin KannChristine E KurschatFranziska Grundmann
Published in: Microorganisms (2021)
The treatment options for cytomegalovirus (CMV) infections in immunosuppressed patients are limited, mainly consisting of (val-)ganciclovir (VGC/GCV) as the first-line treatment. We report on three transplant recipients, one stem cell transplant (allo-HSCT) patient and two kidney transplant (KTx) recipients, with prolonged CMV viremia treated with a combined therapy based on letermovir (LMV), CMV-specific intravenous immunoglobulins (IVIg), and VGC/GCV, which led to the sustained control of CMV viremia in all patients.
Keyphrases
  • end stage renal disease
  • stem cells
  • newly diagnosed
  • chronic kidney disease
  • ejection fraction
  • prognostic factors
  • high dose
  • bone marrow
  • patient reported